Drugs / GNC-035
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05104775 | Feb 2022 → Dec 2025 overdue | hematopoietic and lymphoid cell neoplasm | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05160545 | Nov 2021 → Dec 2025 overdue | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05039931 | Sep 2021 → Jun 2023 | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06066203 | Nov 2023 → Dec 2026 expected | non-Hodgkin lymphoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05944978 | Aug 2023 → Dec 2025 overdue | B-cell chronic lymphocytic leukemia | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNC-035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05160545 ↗ |
| Modality | Monoclonal antibody | “a Tetra-specific Antibody” NCT05039931 ↗ |
| Route | Intravenous | “Administration by intravenous infusion.” NCT05039931 ↗ |